A Pill for Slow-Growing Brain Tumors Used With a Rare Gene Change
Original title: Utility of Vorasidenib in IDH1 R132C-Mutant WHO Grade 2 Astrocytoma: A Case Report.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
The pill is already approved and in guidelines, but this report follows just one person.
The short version
One young man with a rare gene change took a pill, and his leftover tumor stayed stable.
What was studied. Doctors wrote up one patient, a 25-year-old man. He had surgery for a slow-growing brain tumor, then took a pill called vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary.
What they found. Some tumor was left after surgery, and it slowly grew on scans. It went from 7 x 6 mm, to 10x7 mm, then 10x9 mm. He started vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary 40 mg once a day. After 17 months on the pill, the leftover spot had not changed on scans, and he had no side effects from it.
What this means, and what it doesn't
What it could mean: His tumor had a gene change that is not common. This report says the pill could be used safely in his case. The pill is already approved and is in current North American guidelines for some grade 2 tumors when radiation and chemo can wait.
What it doesn't mean: This is a report on one person, not a trial. One case cannot show the pill works better, or even as well, for this rare gene change. The authors say there is still no study that compares the gene changes head to head. It is not a cure, and it is not a promise that your tumor would stay stable.
Source: PubMed, October 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.